同和藥業(300636.SZ):近日取得1項美國發明專利證書
格隆匯3月1日丨同和藥業(300636.SZ)公佈,公司於近日收到美國專利商標局頒發的發明專利證書,發明名稱為克立硼羅的製備方法。
克立硼羅是美國食品藥品監督管理局(即“美國FDA”)近15年來批准的首個治療特應性皮炎的新分子實體藥物,用於3個月及以上嬰幼兒以及成人的中重度濕疹的治療,療效和安全性俱佳,並且具有良好的長期安全性和耐受性。
本發明提供一種新的克立硼羅的製備方法。與現有技術相比,本發明的製備方法具有反應條件温和、收率高、產品質量好、生產成本低的優勢,特別適合於工業化大生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.